Skip to content
value.today

Nacuity Pharmaceuticals, Inc.

🇺🇸 Fort Worth, Texas, USAPharmaceuticalsFounded 2016
Total raised
$31 M
4 rounds on record
Latest round
$8 M
Dec 2025
First round on record
Nov 2016
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Nacuity Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$8 MNo. 4$2 to $10 million

Nacuity Pharmaceuticals, Inc.: Raise no. 4, Dec 2025

Investors in this round

98 investors had bought by the notice of Dec 30, 2025: 98 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $30 M offered; $22 M still to sell
Smallest investment taken
$9,375
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Promissory Notes convertible into preferred stock or common stock, Common Stock Purchase Warrants, Common Stock issued for Warrant Conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$839,335
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Lieser · Executive Officer
  • David Wohlberg · Executive Officer, Director
  • Halden Conner · Executive Officer, Director
  • Jami Kern · Executive Officer
  • Michael Wall · Executive Officer
  • Benjamin Yerxa · Director
  • Emmett Cunningham, Jr. · Director
  • Gerald Cagle · Director
  • Robin Steele · Director
  • Rusty Kelley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “The figure represents the fee on amount sold to date and that Maxim will also receive placement agent warrants.”

Signed by Halden Conner, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 30, 2025. Read the notice at the SEC.

equity, debt, optionsSEC
Mar 2021$12 MNo. 3$10 to $50 million

Nacuity Pharmaceuticals, Inc.: Raise no. 3, Mar 2021

Investors in this round

144 investors had bought by the notice of Jan 3, 2022: 144 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $17 M offered; $6 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Units comprised of Convertible Preferred Shares plus Common Stock Purchase Warrants; Common Stock issued for Warrant conversion; Convertible Preferred Shares issued for exchange of Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,444,673
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Lieser · Executive Officer · Chief Financial Officer
  • David Wohlberg · Executive Officer, Director · Secretary
  • Halden Conner · Executive Officer, Director · President and Chief Executive Officer
  • Benjamin Yerxa · Director
  • Gerald Cagle · Director
  • Robert Ruffolo · Director
  • Robin Steel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · broker-dealer Clifford Adam Teller (CRD 4631188) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Commissions include warrants to purchase 716,949 shares of Common Stock at an exercise price of $0.01 per share.”

Signed by Halden Conner, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 3, 2022. Read the notice at the SEC.

equity, optionsSEC
Jun 2017$9 MNo. 2$2 to $10 million

Nacuity Pharmaceuticals, Inc.: Raise no. 2, Jun 2017

Investors in this round

125 investors had bought by the notice of Jul 20, 2017: 125 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $10 M offered; $1 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, other: Units comprised of Convertible Preferred Shares plus Common Stock Purchase Warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$922,700
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Michael Lieser · Executive Officer · Chief Financial Officer
  • G. Michael Wall, Ph.D. · Executive Officer · Vice President of Research and Development
  • William Halden Conner · Executive Officer, Director · President and Chief Executive Officer
  • David J. Wohlberg · Director
  • Dr. Gerald D. Cagle · Director
  • Isaac Michael Blech · Director
  • Richard Michael Chin, M.D. · Director
  • Sanford J. Hillsberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · broker-dealer Clifford Adam Teller (CRD 4631188) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “Commissions include a Unit Purchase Option to acquire 922,700 Units at an exercise price of $2 per Unit”

Signed by Halden Conner, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 20, 2017. Read the notice at the SEC.

equity, optionsSEC
Nov 2016$2 MNo. 1Under $2 million

Nacuity Pharmaceuticals, Inc.: Raise no. 1, Nov 2016

Investors in this round

46 investors had bought by the notice of Dec 8, 2016: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • William Halden Conner · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Halden Conner, President. Source: SEC Form D, newest notice filed Dec 8, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Nacuity Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2025

That is all the official record says: Nacuity Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Nacuity Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 144 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nacuity Pharmaceuticals, Inc.
NameRoleNamed in
Charles LieserExecutive officerDec 2025
David WohlbergExecutive officerDec 2025
Halden ConnerExecutive officerDec 2025
Jami KernExecutive officerDec 2025
Michael WallExecutive officerDec 2025
Charles Michael LieserChief Financial OfficerJul 2017
G. Michael Wall, Ph.D.Vice President of Research and DevelopmentJul 2017
William Halden ConnerPresident and Chief Executive OfficerJul 2017
Benjamin YerxaDirectorDec 2025
David WohlbergDirectorDec 2025
Emmett Cunningham, Jr.DirectorDec 2025
Gerald CagleDirectorDec 2025
Halden ConnerDirectorDec 2025
Robin SteeleDirectorDec 2025
Rusty KelleyDirectorDec 2025
Robert RuffoloDirectorJan 2022
Robin SteelDirectorJan 2022
David J. WohlbergDirectorJul 2017
Dr. Gerald D. CagleDirectorJul 2017
Isaac Michael BlechDirectorJul 2017
Richard Michael Chin, M.D.DirectorJul 2017
Sanford J. HillsbergDirectorJul 2017
William Halden ConnerPresident and Chief Executive OfficerJul 2017